ARTICLE | Clinical News
Vimpat regulatory update
December 22, 2016 5:25 PM UTC
The European Commission approved an expanded label for Vimpat lacosamide from UCB to include its use as monotherapy to treat partial-onset seizures in patients ages ≥16. Vimpat is approved in the EU a...
BCIQ Company Profiles
BCIQ Target Profiles